SYK and leukemia: Due to the increasingly recognized roles of BCR, Syk and Btk in diseases such as leukemia, lymphoproliferative and inflammatory/autoimmune disorders, potent inhibitors of Syk and Btk were developed over the last 15 years and several of them were validated and approved in clinical studies [3,14,15].